Mabion Launches €500,000 Oncology Services Contest
Mabion, a biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025, aimed at accelerating the development of recombinant protein-based cancer therapies. The contest will culminate at CPHI Worldwide in Frankfurt this October, spotlighting promising biotechs ready to scale their innovation.
"Despite unprecedented scientific advances, many oncology treatments still face hurdles at the funding stage," said Julita Balcerek, COO at Mabion. "This contest is our invitation to innovators who just need the right partner. We’re offering more than a prize; we’re offering a path to impact”.
Selected entrants will be guided through pre-qualification, NDAs, and proposal shaping with Mabion’s business development team.
Rooted in a country that gave the world Marie Curie and other scientific pioneers, Mabion builds on Poland’s legacy of innovation. From groundbreaking research in radioactivity to modern-day biomanufacturing, the spirit of Polish science lives on in every partnership we forge. Lodz, once a global textile hub, is now a rising force in life sciences, and Mabion is helping shape that transformation.
An independent jury of experts will evaluate entries based on scientific merit, feasibility, and potential patient impact. The winner will receive a €500,000 credit toward Mabion’s integrated CDMO capabilities, including process and analytical development, upstream/downstream processing, and clinical supply manufacturing. Runner-up entries may also be invited into partnership discussions, reinforcing Mabion’s focus on long-term collaboration.
"Wherever you’re based, this is your chance to accelerate your breakthrough program with Mabion’s financial support and world class services," Balcerek added. "Mabion is proud to help turn scientific ambition into clinical reality.”
More details can be found here
Mabion Competition
